Advanced Malignancies Clinical Trial
Official title:
Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
| Verified date | December 2023 |
| Source | Novartis |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
The purpose of this first-in-human study of MBG453 was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MBG453 administered i.v. as a single agent or in combination with PDR001 or decitabine in adult patients with advanced solid tumors
| Status | Terminated |
| Enrollment | 252 |
| Est. completion date | August 30, 2022 |
| Est. primary completion date | August 30, 2022 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Histologically documented advanced or metastatic solid tumors. - Phase I-Ib part (including dose ranging part): Patients with advanced/metastatic solid tumors, with measurable or non-measurable disease as determined by RECIST v1.1, who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists and who did not receive prior anti-PD-1/PD-L1 treatment. - Phase II part (MBG453 single agent): Patients with advanced/metastatic solid tumors in the indication in which at least one confirmed PR or CR was seen during the dose escalation phase I part. Patients must have measurable disease as determined by RECIST v1.1, have progressed despite standard therapy or be intolerant to standard therapy. - Phase II part (MBG453 in combination PDR001): Patients with advanced/metastatic tumors in the below selected indications, with at least one measurable lesion as determined by RECIST v1.1, who have received standard therapy and are intolerant of standard therapy or have progressed following their last prior therapy.: - Melanoma (anti-PD-1/PD-L1 therapy naïve or pre-treated) - Non small cell lung cancer (anti-PD-1/PD-L1 therapy naïve or pre-treated) - Renal Cell Carcinoma (anti-PD-1/PD-L1 therapy naïve or pre-treated) - Must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy at screening/baseline, and during therapy on the study. - For MBG453 in combination with decitabine: anti-PD-1/PD-L1 therapy naïve SCLC patients who have failed no more than two lines of standard chemotherapy including topotecan Exclusion Criteria: - Presence of symptomatic central nervous system metastases. - History of severe hypersensitivity reactions to other monoclonal antibodies. - Human Immunodeficiency Virus, Hepatitis B Virus or Hepatitis C Virus infection. - Active autoimmune disease or a documented history of autoimmune disease, including ulcerative colitis and Crohn's disease or any condition that requires systemic steroids. - Systemic steroid therapy or any immunosuppressive therapy (=10mg/day prednisone or equivalent). - Use of any vaccines against infectious diseases (e.g. varicella, pneumococcus) within 4 weeks of initiation of study treatment. - Pre-treatment with anti-CTLA4 antibodies in combination with any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathway. - Participation in an interventional, investigational non-immunotherapy study within 2 weeks of the first dose of study treatment. - Prior participation in an interventional, investigational cancer vaccine or immunotherapy study except for an anti-PD-1/PD-L1 study. - For MBG453 in combination with decitabine: Hypersensitivity to decitabine or to any of the excipients, listed in decitabine country specific label |
| Country | Name | City | State |
|---|---|---|---|
| Canada | Novartis Investigative Site | Toronto | Ontario |
| Italy | Novartis Investigative Site | Milano | MI |
| Italy | Novartis Investigative Site | Rozzano | MI |
| Japan | Novartis Investigative Site | Kashiwa | Chiba |
| Korea, Republic of | Novartis Investigative Site | Seoul | |
| Netherlands | Novartis Investigative Site | Amsterdam | |
| Netherlands | Novartis Investigative Site | Leiden | |
| Singapore | Novartis Investigative Site | Singapore | |
| Switzerland | Novartis Investigative Site | Geneve 14 | |
| Taiwan | Novartis Investigative Site | Taipei | |
| United States | Sidney Kimmel CCC At JH Sidney Kimmel CCC | Baltimore | Maryland |
| United States | Dana Farber Cancer Institute DFCI - Brookline | Boston | Massachusetts |
| United States | UT M.D Anderson Cancer Center | Houston | Texas |
| United States | Mays Cancer Ctr Uthsa Mdacc | San Antonio | Texas |
| Lead Sponsor | Collaborator |
|---|---|
| Novartis Pharmaceuticals |
United States, Canada, Italy, Japan, Korea, Republic of, Netherlands, Singapore, Switzerland, Taiwan,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Phase I-Ib and Dose Ranging Part: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period | Number of participants with AEs (any AE regardless of seriousness) and SAEs, including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs.
AE grades to characterize the severity of the AEs were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. For CTCAE v4.03, Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death related to AE. The on-treatment period is defined from the day of first administration of study treatment up to 30 days after the date of its last administration. |
From first dose of study medication up to 30 days after last dose, with a maximum duration of 2 years for sabatolimab and 5 years for sabatolimab in combination with spartalizumab | |
| Primary | Phase I-Ib: Number of Participants With Dose-Limiting Toxicities (DLTs) | A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade = 3 assessed as unrelated to disease, disease progression, inter-current illness or concomitant medications, which occurs within the first cycle of treatment with sabatolimab as single agent or in the first two cycles of treatment when sabatolimab is given in combination with spartalizumab during the dose escalation part of the study. Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher. The duration of one treatment cycle is 28 days. | 28 days (sabatolimab single agent) and 56 days (sabatolimab+spartalizumab) | |
| Primary | Phase I-Ib and Dose Ranging Part: Number of Participants With Dose Reductions and Dose Interruptions of Sabatolimab | Number of participants with at least one dose reduction of sabatolimab and number of participants with at least one dose interruption of sabatolimab. | From first dose of study medication up to last dose, with a maximum duration of 1.9 years for sabatolimab and 4.9 years for sabatolimab in combination with spartalizumab | |
| Primary | Phase Ib: Number of Participants With Dose Reductions and Dose Interruptions of Spartalizumab | Number of participants with at least one dose reduction of spartalizumab and number of participants with at least one dose interruption of spartalizumab. | From first dose of study medication up to last dose, with a maximum duration of 4.9 years | |
| Primary | Phase I-Ib and Dose Ranging Part: Dose Intensity of Sabatolimab | Dose intensity of sabatolimab Q2W was calculated as cumulative actual dose in milligrams divided by duration of exposure in days and then multiplied by 14 days.
Dose intensity of sabatolimab Q4W was calculated as cumulative actual dose in milligrams divided by duration of exposure in days and then multiplied by 28 days. |
From first dose of study medication up to last dose, with a maximum duration of 1.9 years for sabatolimab and 4.9 years for sabatolimab in combination with spartalizumab | |
| Primary | Phase Ib: Dose Intensity of Spartalizumab | Dose intensity of spartalizumab Q2W was calculated as cumulative actual dose in milligrams divided by duration of exposure in days and then multiplied by 14 days.
Dose intensity of spartalizumab Q4W was calculated as cumulative actual dose in milligrams divided by duration of exposure in days and then multiplied by 28 days. |
From first dose of study medication up to last dose, with a maximum duration of 4.9 years | |
| Primary | Phase II: Overall Response Rate (ORR) Per RECIST v1.1 | Tumor response was based on local investigator assessment as per Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. ORR per RECIST v1.1 is defined as the percentage of participants with a best overall response of Complete Response (CR) or Partial Response (PR).
For RECIST v1.1, CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR= At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. |
From start of treatment until end of treatment, assessed up to 2.9 years | |
| Secondary | Best Overall Response (BOR) Per RECIST v1.1 | BOR is defined as the best response recorded from the start of the study treatment until disease progression/recurrence, based on local investigator assessment per RECIST v1.1.
For RECIST v1.1, CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters; PD= At least a 20% increase in the sum of diameters of all measured target lesions, taking as reference the smallest sum of diameter of all target lesions recorded at or after baseline. In addition, the sum must also demonstrate an absolute increase of at least 5 mm; SD= Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progression; NCRNPD: Persistence of one or more non-target lesions. Number of participants in each category is reported in the table. |
From start of treatment until end of treatment, assessed up to 1.9 years for sabatolimab and 4.9 years for sabatolimab in combination with spartalizumab | |
| Secondary | Progression-Free Survival (PFS) Per RECIST v1.1 | PFS is defined as the time from the date of start of treatment to the date of the first documented progression or death due to any cause. If a patient did not have an event, PFS was censored at the date of the last adequate tumor assessment. Tumor response was based on local investigator assessment per RECIST v1.1.
PFS was analyzed using Kaplan-Meier estimates. |
From start of treatment until first documented progression or death due to any cause, assessed up to 1.9 years for sabatolimab and 4.9 years for sabatolimab in combination with spartalizumab | |
| Secondary | Duration of Response (DOR) Per RECIST v1.1 | DOR only applies to patients for whom best overall response is complete response (CR) or partial response (PR) based on local investigator assessment according to RECIST v1.1. DOR is defined as the time from the date of first documented response to the date of first documented progression or death due to underlying cancer. If a patient did not have an event, duration was censored at the date of last adequate tumor assessment.
According to the statistical analysis plan (SAP), summary estimates of DOR using the Kaplan-Meier method were planned to be reported if there were at least 10 patients achieving a confirmed CR or PR in each treatment group/arm. |
From first documented response to first documented disease progression or death due to underlying cancer, assessed up to 1.9 years for sabatolimab and 4.9 years for sabatolimab in combination with spartalizumab | |
| Secondary | Overall Response Rate (ORR) Per irRC | Tumor response was based on local investigator assessment as per irRC. ORR per irRC is defined as the percentage of participants with a best overall response of immune related Complete Response (irCR) or immune related Partial Response (irPR).
For irRC, irCR=Disappearance of all non-nodal target lesions and non-target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to < 10 mm; irPR= At least a 30% decrease in the sum of diameters of all target lesions including new measurable lesions, taking as reference the baseline sum of diameters. |
From start of treatment until end of treatment, assessed up to 1.9 years for sabatolimab and 4.9 years for sabatolimab in combination with spartalizumab | |
| Secondary | Progression-Free Survival (PFS) Per irRC | PFS is defined as the time from the date of start of treatment to the date of the first documented and confirmed progression or death due to any cause. If a patient did not have an event, PFS was censored at the date of the last adequate tumor evaluation. Tumor response was based on local investigator assessment per irRC.
PFS was analyzed using Kaplan-Meier estimates. |
From start of treatment until first documented and confirmed progression or death due to any cause, assessed up to 1.9 years for sabatolimab and 4.9 years for sabatolimab in combination with spartalizumab | |
| Secondary | Overall Survival (OS) | OS is defined as the time from date of start of treatment to date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last known date patient alive.
OS was estimated using Kaplan-Meier estimates. |
From start of treatment until death due to any cause, assessed up to 2 years for sabatolimab and 5.3 years for sabatolimab in combination with spartalizumab | |
| Secondary | Maximum Observed Serum Concentration (Cmax) of Sabatolimab | Pharmacokinetic (PK) parameters were calculated based on sabatolimab serum concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed serum concentration following a dose. | pre-infusion and 1, 24, 168, 240 and 336 hours after completion of the sabatolimab infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of the infusion was 30 minutes. The duration of one cycle was 28 days. | |
| Secondary | Time to Reach Maximum Serum Concentration (Tmax) of Sabatolimab | PK parameters were calculated based on sabatolimab serum concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) serum concentration following a dose. Actual recorded sampling times were considered for the calculations. | pre-infusion and 1, 24, 168, 240 and 336 hours after completion of the sabatolimab infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of the infusion was 30 minutes. The duration of one cycle was 28 days. | |
| Secondary | Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Sabatolimab | PK parameters were calculated based on sabatolimab serum concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation. | pre-infusion and 1, 24, 168, 240 and 336 hours after completion of the sabatolimab infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of the infusion was 30 minutes. The duration of one cycle was 28 days. | |
| Secondary | Terminal Elimination Half-life (T1/2) of Sabatolimab | PK parameters were calculated based on sabatolimab serum concentrations by using non-compartmental methods. T1/2 was calculated by regression analysis of the terminal elimination phase. T1/2 was computed as 0.693/terminal elimination rate constant. | pre-infusion and 1, 24, 168, 240 and 336 hours after completion of the sabatolimab infusion on Cycle 3 Day 1. The duration of the infusion was 30 minutes. The duration of one cycle was 28 days. | |
| Secondary | Maximum Observed Serum Concentration (Cmax) of Spartalizumab | PK parameters were calculated based on spartalizumab serum concentrations by using non-compartmental methods. Cmax is defined as the maximum (peak) observed serum concentration following a dose. | pre-infusion and 1, 24, 168, 240 and 336 hours after completion of the spartalizumab infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of the infusion was 30 minutes. The duration of one cycle was 28 days. | |
| Secondary | Time to Reach Maximum Serum Concentration (Tmax) of Spartalizumab | PK parameters were calculated based on spartalizumab serum concentrations by using non-compartmental methods. Tmax is defined as the time to reach maximum (peak) serum concentration following a dose. Actual recorded sampling times were considered for the calculations. | pre-infusion and 1, 24, 168, 240 and 336 hours after completion of the spartalizumab infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of the infusion was 30 minutes. The duration of one cycle was 28 days. | |
| Secondary | Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of Spartalizumab | PK parameters were calculated based on spartalizumab serum concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUClast calculation. | pre-infusion and 1, 24, 168, 240 and 336 hours after completion of the spartalizumab infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of the infusion was 30 minutes. The duration of one cycle was 28 days. | |
| Secondary | Terminal Elimination Half-life (T1/2) of Spartalizumab | PK parameters were calculated based on spartalizumab serum concentrations by using non-compartmental methods. T1/2 was calculated by regression analysis of the terminal elimination phase. T1/2 was computed as 0.693/terminal elimination rate constant. | pre-infusion and 1, 24, 168, 240 and 336 hours after completion of the spartalizumab infusion on Cycle 3 Day 1. The duration of the infusion was 30 minutes. The duration of one cycle was 28 days. | |
| Secondary | Number of Participants With Anti-sabatolimab Antibodies | Immunogenicity was evaluated in serum in a validated three-tiered assay approach. Samples were screened for potential anti-sabatolimab antibodies and positive screen results were confirmed using a confirmatory assay. For confirmed anti-drug antibodies (ADA) positive samples, titers were determined. Patient ADA status was defined as follows:
ADA-negative at baseline: ADA-negative sample at baseline ADA-positive at baseline: ADA-positive sample at baseline ADA-negative post-baseline: patient with ADA-negative sample at baseline and at least 1 post baseline determinant sample, all of which are ADA-negative samples ADA-inconclusive post-baseline = patient who does not qualify as ADA-positive or ADA-negative Treatment-induced ADA-positive = ADA-negative sample at baseline and at least 1 treatment-induced ADA-positive sample Treatment-boosted ADA-positive = ADA-positive sample at baseline and at least 1 treatment-boosted ADA-positive sample |
Baseline (before first dose) and post-baseline (assessed throughout the treatment up to 1.9 years for sabatolimab and 4.9 years for sabatolimab in combination with spartalizumab) | |
| Secondary | Number of Participants With Anti-spartalizumab Antibodies | Immunogenicity was evaluated in serum in a validated three-tiered assay approach. Samples were screened for potential anti-spartalizumab antibodies and positive screen results were confirmed using a confirmatory assay. For confirmed anti-drug antibodies (ADA) positive samples, titers were determined. Patient ADA status was defined as follows:
ADA-negative at baseline: ADA-negative sample at baseline ADA-positive at baseline: ADA-positive sample at baseline ADA-negative post-baseline: patient with ADA-negative sample at baseline and at least 1 post baseline determinant sample, all of which are ADA-negative samples ADA-inconclusive post-baseline = patient who does not qualify as ADA-positive or ADA-negative Treatment-induced ADA-positive = ADA-negative sample at baseline and at least 1 treatment-induced ADA-positive sample Treatment-boosted ADA-positive = ADA-positive sample at baseline and at least 1 treatment-boosted ADA-positive sample |
Baseline (before first dose) and post-baseline (assessed throughout the treatment up to 4.9 years). | |
| Secondary | Baseline Expression of PD-L1 | The tumor expression of programmed cell death-ligand 1 (PD-L1) was measured by immunohistochemical methods. This record summarizes the baseline expression of PD-1 and the clinical benefit of study treatment. Clinical benefit (BOR: CR, PR, SD or NCRNPD) and No clinical benefit (BOR: PD) was based on local investigator assessment per RECIST v1.1. | Screening | |
| Secondary | Baseline Expression of CD8+ | The tumor expression of CD8+ was measured by immunohistochemical methods. This record summarizes the baseline expression of CD8+ and the clinical benefit of study treatment. Clinical benefit (BOR: CR, PR, SD or NCRNPD) and No clinical benefit (BOR: PD) was based on local investigator assessment per RECIST v1.1. | Screening | |
| Secondary | Baseline Expression of TIM-3 | The tumor expression of T-cell Immunoglobulin domain and Mucin domain-3 (TIM-3) was measured by immunohistochemical methods. This record summarizes the baseline expression of TIM-3 and the clinical benefit of study treatment. Clinical benefit (BOR: CR, PR, SD or NCRNPD) and No clinical benefit (BOR: PD) was based on local investigator assessment per RECIST v1.1. | Screening | |
| Secondary | Baseline Expression of LAG-3 | The tumor expression of lymphocyte-activation gene-3 (LAG-3) was measured by immunohistochemical methods. This record summarizes the baseline expression of LAG-3 and the clinical benefit of study treatment. Clinical benefit (BOR: CR, PR, SD or NCRNPD) and No clinical benefit (BOR: PD) was based on local investigator assessment per RECIST v1.1. | Screening | |
| Secondary | Baseline Expression of CD163 | The tumor expression of CD163 was measured by immunohistochemical methods. This record summarizes the baseline expression of CD163 and the clinical benefit of study treatment. Clinical benefit (BOR: CR, PR, SD or NCRNPD) and No clinical benefit (BOR: PD) was based on local investigator assessment per RECIST v1.1. | Screening | |
| Secondary | Percentage Change From Baseline of Tumor Infiltrating Lymphocytes (TILs) Count | The count of TILs was performed by hematoxylin and eosin stain. | Baseline (screening) and post-baseline (assessed throughout the treatment up to maximum 193 days) | |
| Secondary | Phase II: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) During the On-treatment Period | Number of participants with AEs and SAEs, including changes from baseline in vital signs, electrocardiograms and laboratory results qualifying and reported as AEs.
AE grades to characterize the severity of the AEs were based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. For CTCAE v4.03, Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening; Grade 5 = death related to AE. The on-treatment period is defined from the day of first administration of study treatment up to 30 days after the date of its last administration. |
From first dose of study medication up to 30 days after last dose, with a maximum duration of 3 years | |
| Secondary | Phase II: Number of Participants With Dose Reductions and Dose Interruptions of Sabatolimab | Number of participants with at least one dose reduction of sabatolimab and number of participants with at least one dose interruption of sabatolimab. | From first dose of study medication up to last dose, with a maximum duration of 2.9 years | |
| Secondary | Phase II: Number of Participants With Dose Reductions and Dose Interruptions of Spartalizumab | Number of participants with at least one dose reduction of spartalizumab and number of participants with at least one dose interruption of spartalizumab. | From first dose of study medication up to last dose, with a maximum duration of 2.9 years | |
| Secondary | Phase II: Dose Intensity of Sabatolimab | Dose intensity of sabatolimab was calculated as cumulative actual dose in milligrams divided by duration of exposure in days and then multiplied by 28 days. | From first dose of study medication up to last dose, with a maximum duration of 2.9 years | |
| Secondary | Phase II: Dose Intensity of Spartalizumab | Dose intensity of spartalizumab was calculated as cumulative actual dose in milligrams divided by duration of exposure in days and then multiplied by 28 days. | From first dose of study medication up to last dose, with a maximum duration of 2.9 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
| Completed |
NCT00948961 -
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
|
Phase 1/Phase 2 | |
| Completed |
NCT03297424 -
A Study of PLX2853 in Advanced Malignancies.
|
Phase 1 | |
| Terminated |
NCT02265510 -
An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT03907969 -
A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.
|
Phase 1/Phase 2 | |
| Completed |
NCT03241173 -
A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT02923349 -
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT04025957 -
A Study of SHR-1501 in Patients With Advanced Tumors
|
Phase 1 | |
| Recruiting |
NCT05048134 -
A Phase I Study of HRS2300 or Combined With SHR-1316 or SHR-1701 or Trametinib or Almonertinib in Patients With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT00651664 -
A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT06038058 -
A Phase I Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT00611793 -
PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies
|
Phase 1 | |
| Recruiting |
NCT05891171 -
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
|
Phase 1 | |
| Not yet recruiting |
NCT05987605 -
Clinical Study of 1A46 Drug Substance
|
Phase 1 | |
| Terminated |
NCT03277352 -
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05577182 -
Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT04831996 -
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.
|
Phase 1 | |
| Recruiting |
NCT06468098 -
A Study of IBI363 in Subjects With Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT02737501 -
ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants
|
Phase 3 | |
| Completed |
NCT03158272 -
A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread
|
Phase 1 |